ç°å¢åé¡ãªã©ã«å£°ããããè¥ãä¸ä»£ããã®å£°ã«ã大人ã¯ã©ãåãåã£ã¦è¡ãã¹ããªã®ãã10代ã¨åãåãç¶ããNPOæ³äººçäºé·ã«èãã¾ããã

ã¨ã¹ããã¢å½æï¼å·¦ï¼ã¨æ¬§å·æï¼å³ã2017å¹´6æ29æ¥æ®å½±ãè³æåçï¼ã(c)Petras Malukas / AFP ã2æ18æ¥ AFPãã¨ã¹ããã¢ã®å¯¾å¤æ å ±æ©é¢ã¯17æ¥çºè¡¨ã®å¹´æ¬¡å ±åæ¸ã§ãä¸å½ã¯å彿¿åºãæ¯é ãããæ²é»ã®ä¸çããæãã§ããã¨ææããå¢å¤§ããåå½ã®å½±é¿åã«è¦ææã示ããã ã¾ããä¸çãä¸å½ã®ãã¯ããã¸ã¼ã¸ã®ä¾åãå¼·ãã¦ãããã¨ããä¸å½ãããã·ã¢ã«å£ã£ã¦ã彿 å ±ãæ¡æ£ãã¦ãããã¨ã«ãè¨åããã åæ©é¢ã¯ããä¸å½ã®ä¸»è¦ç®æ¨ã¯ãç±³å½ã¨æ¬§å·ãåæãããã¨ã ãã¨ææããä¸å½ã¯ãåè£ããæ¬§å·ãæããã«è¶³ãããç±³å½ã»ã©æ¿ããæµæãããã¨ã¯ã¾ããªãã¨é常ã«ããçè§£ãã¦ããã ããã«ããä¸å½ã®å¤äº¤æ¿çç念ã®å®è·µãã人é¡éå½å ±åä½ãã®æ§ç¯ã¯ãä¸å½æ¿åºã«æ¯é ãããæ²é»ã®ä¸çã«ã¤ãªãããã¨ä¸»å¼µããã ã¨ã¹ããã¢ã¯å¾æ¥ãå½å¢ãæ¥ãã大å½ãã·ã¢ã«æ¸å¿µã示ãã¦ããããè¿å¹´ã¯ä¸å½ã®å½±é¿åã¸ã®æ¸å¿µã訴ã
ããã«ã¡ã¯ã ä»åã¯å·®ãè¾¼ã¿ã®å¤ããããã¯ãéçºã«ãããã¹ã±ã¸ã¥ã¼ã«ç²¾åº¦ã®ä¸ãæ¹ã¨ãã¦ããã¼ã³ã¢ãããã£ã¼ãã®å©ç¨ããããããããã¨æãã¾ãã ã©ããªäººã«èªãã§ã»ããã Product GrowthãEnhancementã«æºãã£ã¦ãããã©ããããã¨ãå¤ãã¦æã£ãããã«é²æã管çã§ããªã人 âã®ãããªProduct Manager(PdM)ãProject Manager(PjM)ã¨ã®ã³ãã¥ãã±ã¼ã·ã§ã³ãå¤ããã©ãæå¾ ã«å¯¾ãã¦ãã¾ãåãã¦ãããªããã¨ããã©ãããæã£ã¦ãæ¹ TL;DR 3ã¶æã6ã¶æç¨åº¦ã§ã¿ã¤ã ããã¯ã¹ãåãã¾ããã ã¿ã¤ã ããã¯ã¹ã®ä¸ã§ãããããã¨ãå ¨é¨ãªã¹ãã¢ãããã¦è¦ç©ããããã¾ããã çµãã£ãã¿ã¹ã¯ã®closeã¨æ°è¦ã¿ã¹ã¯ã®ãªã¹ãã¢ãããç¹°ãè¿ãã¨ãèªç¶ã¨ããããããã¨ãå ¨é¨ã§ããã®ãã©ããããè¦ããåãã¾ã ãã¼ã³ã¢ãããã£ã¼ãã¨ã¯ ä¸è¨ã®ãããªãã®ã§ãã å³ä¸ã®
ã2æ18æ¥ AFPãå°æ¹¾ã®è¡çç¸ã¯17æ¥ãæ°åã³ããã¦ã¤ã«ã¹ã¯ã¯ãã³500ä¸ååã確ä¿ããè¨ç»ããæ¿æ²»çå§åãã«ããæçµæ®µéã§é æ«ããã¨è¨´ãããä¸å½ãå°æ¹¾ã®ã¯ã¯ãã³æ¥ç¨®ã妨害ãããã¨ãã¦ããæããããã¨ã®æ¸å¿µãçãã¦ããã 鳿ä¸ï¼Chen Shih-chungï¼è¡çç¸ã¯ã©ã¸ãªå±ã®åæã«å¯¾ãã米製è¬å¤§æãã¡ã¤ã¶ã¼ï¼Pfizerï¼ã¨ç¬è£½è¬ãã³ãã£ã¼ã®ããªã³ããã¯ï¼BioNTechï¼ãå ±åéçºããã¯ã¯ãã³ã確ä¿ããããã«ããªã³ããã¯ã¨è¡ã£ã¦ããéè¦ãªäº¤æ¸ããæçµæ®µéã§ã決è£ããã¨æãããã 鳿°ã¯ãæ¿æ²»çå§åããã£ããã¨ã¿ã¦ããããåæãæç«ããªãã£ãã®ã¯ãå°æ¹¾ããã¾ãã«åã¶ã®ã好ã¾ãªãè ãããããã ãã¨è¿°ã¹ãã ããªã³ããã¯ã¯ä¸å½å»è¬å大æã®ä¸æµ·å¾©æå»è¬éå£ï¼Shanghai Fosun Pharmaceutical Groupï¼ã¨ãåå½ã¸ã®ã³ããã¯ã¯ãã³æä¾å¥ç´ãçµãã§ããã ä¸å½ã交æ¸
NHKã§æ¾éã®ã夫婦å¥å§âçµå©âã§ããªããµããã®åææ¥è¨ã çªçµã®æå¾10åã§å対派ã®äºäºé馿°ã«ã¤ã³ã¿ãã¥ã¼ ç»åå¼ç¨å ï¼https://pbs.twimg.com/media/E3IHQIsUcAgqXoD?format=jpg&name=medium è¡è°é¢è°å¡ã13æåããé輸大è£ï¼ç¬¬69代ï¼ã建è¨å¤§è£ï¼ç¬¬64代ï¼ã èªç±æ°ä¸»å æ¿å調æ»ä¼é·ï¼ç¬¬43代ï¼ã彿°æ°å 代表ï¼ç¬¬2代ï¼ã å é£åºç¹å½æ å½å¤§è£ï¼éèæ å½ï¼ãªã©ãæ´ä»»ããã 2017å¹´10æ5æ¥ã«ãå°å ã§ããåºå³¶çå°¾éå¸ã§ ãä¸ç·ã«ãã£ã¦ããç¸æ£ãè¦ã¤ããããã«ãªãããªã©ã®çç±ããã 第48åè¡è°é¢è°å¡ç·é¸æã«ç«åè£ããªããã¨ã表æããã 2019å¹´5æ21æ¥çºä»¤ã®æ¥ã®åå²ã§ãææ¥å¤§ç¶¬ç« ãåç« ã äºäºé馿°ã夫婦ã«è¨ã£ãè¸ç³ã®è¨èä¸è¦§ äºäºéé¦ãããããã¡ã¯ããããããããããããã¨ããã¦çãã¦ãããªãããã®ï¼ã 夫婦ããäºãã®å
ããåãã¦ãããéãããããã¹ãããã¤ãã¢ããªãã¿ã¤ãã¼ããéå¶ããæ ªå¼ä¼ç¤¾ã¿ã¤ãã¼ï¼æå¨å°ï¼æ±äº¬é½è±å³¶åºã代表åç· å½¹ï¼å°å·å¶ºï¼ã¯2021å¹´2æ16æ¥ã®æç¥çã®å¤§æç§ç« ç¥äºã®ãªã³ã¼ã«éåã«é¢ããå ±éã«é¢é£ããäºå®ç¢ºèªãé²ããã¨ã¨ãã«ãåçºé²æ¢ã«åãã¦ã¯ã¼ã«ã¼æ§ããã®ç¸è«ã»éå ±ã®å°ç¨çªå£ãè¨ç½®ãããªã©ãã¯ã¼ã«ã¼æ§ã®ãµãã¼ãä½å¶ãããä¸å±¤å¼·åãããã¾ãã ãã®ãã³ã¯å¤ãã®çæ§ã«ãå¿é ãããããã¦ãããå¿ãããè©«ã³ç³ãä¸ãã¾ãã æç¥çã®å¤§æç§ç« ç¥äºã®ãªã³ã¼ã«éåã«ããã¦éããããç½²åã®ä¸ã«ãå½é ãçããããã®ããã£ããã¨ãå ±éããã¦ããã¾ããããã«é¢é£ãã¦ãä¸é¨ï¼³ï¼®ï¼³çã§ãå½è©²å½é ã«ååããã¢ã«ãã¤ãã®åéã®ããã«ç¨ããããæ±äººåªä½çã®ä¸ã¤ã«ãå¼ç¤¾ãµã¼ãã¹ãããã¨ã®ãææããããã¾ããã å¼ç¤¾ã«ããã¦ããå ±éãå½è©²ãææçãåããæ©æ¥ã«ç¤¾å ã§èª¿æ»ããã¨ãããé¢é£ããã¨æãããæ±äººãéå»ã«åå¨ã
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}